Scotiabank raised the firm’s price target on Guardant Health (GH) to $57 from $52 and keeps an Outperform rating on the shares. The company’s Q1 revenues beat expectations, and its FY revenue guidance was raised, the analyst tells investors. The firm believes the company is well-positioned to deliver outsized growth, driven by its competitive strength, ASP growth, and real-world evidence platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Cathie Wood Loses Confidence in Palantir Stock (PLTR) Ahead of Q1 Earnings
- Guardant Health Reports Strong Q1 Revenue Growth
- Cathie Wood’s ARK Investment buys 186.8K shares of Guardant Health today
- Guardant Health price target raised to $60 from $56 at TD Cowen
- Guardant Health price target raised to $70 from $65 at UBS